Compounds > enkephalin-leu--ala(2)-arg(6)-

enkephalin-leu--ala(2)-arg(6)- and Hemorrhage

enkephalin-leu--ala(2)-arg(6)- has been researched along with Hemorrhage* in 1 studies

Other Studies

1 other study(ies) available for enkephalin-leu--ala(2)-arg(6)- and Hemorrhage

Article	Year
[Dalargin--a peptide preparation with cytoprotective action]. Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR, 1985, Volume: 8, Issue:2 The role and possible clinical use of regulatory peptides, a new type of regulatory substances, is discussed. Special attention is paid to the opioid peptides and their analogues. The new drug dalargin has been developed on the basis of the endogenous opioid peptide leucine-encephalin. Its action has been studied using experimental models. It has been established that the optimal dose (10 micrograms/kg) of dalargin is effective in preventing ulceration in the cystamine duodenal ulcer rat model and the development of stomach erosive lesions in immobilization stress, reducing the degree of liver degeneration in CCl4 poisoning, etc. With an increase of the dose of dalargin the effect "escapes". Dalargin is primarily bound by delta-receptors, it produces no analgetic effect and does not enter the brain. Dalargin exhibits a pronounced cytoprotective and regeneratory action and may take an important place in treating the internal organ diseases. Topics: Animals; Carbon Tetrachloride Poisoning; Cells, Cultured; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Duodenal Ulcer; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Hemorrhage; Humans; Lymphocytes; Mice; Necrosis; Pancreas; Rats; Receptors, Opioid; Stomach Ulcer	1985

Article

Year

[Dalargin--a peptide preparation with cytoprotective action].

Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR, 1985, Volume: 8, Issue:2

The role and possible clinical use of regulatory peptides, a new type of regulatory substances, is discussed. Special attention is paid to the opioid peptides and their analogues. The new drug dalargin has been developed on the basis of the endogenous opioid peptide leucine-encephalin. Its action has been studied using experimental models. It has been established that the optimal dose (10 micrograms/kg) of dalargin is effective in preventing ulceration in the cystamine duodenal ulcer rat model and the development of stomach erosive lesions in immobilization stress, reducing the degree of liver degeneration in CCl4 poisoning, etc. With an increase of the dose of dalargin the effect "escapes". Dalargin is primarily bound by delta-receptors, it produces no analgetic effect and does not enter the brain. Dalargin exhibits a pronounced cytoprotective and regeneratory action and may take an important place in treating the internal organ diseases.

Topics: Animals; Carbon Tetrachloride Poisoning; Cells, Cultured; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Duodenal Ulcer; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Hemorrhage; Humans; Lymphocytes; Mice; Necrosis; Pancreas; Rats; Receptors, Opioid; Stomach Ulcer

1985